EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Topical formulation of repurposed FDA-approved compounds inhibits Pseudomonas aeruginosa ExoU and improves corneal infection outcomes

Daniel M Foulkes iD, David G Fernig, Keri McLean, Marie Held, John A Harris, Yan Sun, Joanne L Fothergill, Valerie Price, Dominic P Byrne, Gabriela Czanner, Connie Tam, Stephen B Kaye

PLOS Pathogens · 03.08.2026 · 22 (8) · e1014474

DOI: 10.1371/journal.ppat.1014474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 03.08.2026. Verfasst von Daniel M Foulkes und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Eye and Vision Sciences, Institute of Life Course and Medical Sciences (ILCAMS), University of Liverpool, Liverpool, United Kingdom. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Pseudomonas Infections, Anti-Bacterial Agents, Keratitis. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council (BBSRC), Fight for Sight UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microbial keratitis caused by Exotoxin U (ExoU)-producing strains of Pseudomonas aeruginosa is associated with poor clinical outcomes and reduced responsiveness to antimicrobial therapy. ExoU, a phospholipase, is secreted directly into host cells, causing their lysis. A screen of 3,034 FDA-approved compounds identified zinc pyrithione (Zp), bismuth subcitrate (Bis), and polymyxin B (Pol) as lead inhibitors of ExoU selectively inhibiting it without affecting human PLA2s or bacterial viability. The compounds have distinct inhibitory mechanisms: Zp disrupted ExoU oligomerization and protein stability; Bis impaired phosphatidylinositol 4,5-bisphosphate-dependent membrane association; Pol directly inhibited catalysis via its lipid-peptide architecture. Compound combinations enhanced ExoU inhibition in vitro to nanomolar concentrations. In mammalian cells, Bis and Pol promoted lysosomal trafficking and degradation of ExoU. A high content screen of 52 P. aeruginosa keratitis isolates demonstrated the broad efficacy of these inhibitors in exoU ⁺ strains. Therapeutic efficacy was evaluated in ex vivo porcine corneas, Galleria mellonella , and in vivo mouse keratitis models. Topical delivery of ExoU inhibitors, particularly in combination, significantly reduced corneal opacity, ulceration, and stromal damage in porcine corneas without affecting bacterial load. In Galleria , compound combinations significantly maintained larval health, improved larval survival and delayed mortality. In a mouse eye infection model, combinatorial treatment reduced disease severity and preserved tissue viability without altering bacterial burden. These findings validate ExoU as a druggable virulence factor and support the repurposing of these compounds as an antivirulence strategy for the treatment of P. aeruginosa infections in human beings and in veterinary medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaPseudomonas InfectionsAnti-Bacterial AgentsKeratitisBacterial ProteinsEye Infections, BacterialAnimalsHumansMiceSwineDrug RepositioningCorneaAdministration, Topical

Substanzen

Anti-Bacterial AgentsBacterial Proteins

Autor:innen und Institutionen

  • Department of Eye and Vision Sciences, Institute of Life Course and Medical Sciences (ILCAMS), University of Liverpool, Liverpool, United Kingdom.
  • Department of Biochemistry, Cell and Systems biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
  • Centre for Cell Imaging, Technology, Infrastructure and Environment Directorate, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom.
  • Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
  • Department of Ophthalmic Research, Cleveland Clinic Research, Cleveland, Ohio, United States of America.
  • Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool, United Kingdom.

ORCID-Profile: Daniel M Foulkes

Förderung

  • Biotechnology and Biological Sciences Research Council (BBSRC)
  • Fight for Sight UK

Zitieren

APA

Foulkes, D. M., Fernig, D. G., McLean, K., Held, M., Harris, J. A., Sun, Y., Fothergill, J. L., Price, V., Byrne, D. P., Czanner, G., Tam, C., & Kaye, S. B. (2026). Topical formulation of repurposed FDA-approved compounds inhibits Pseudomonas aeruginosa ExoU and improves corneal infection outcomes. PLOS Pathogens, 22(8), e1014474. https://doi.org/10.1371/journal.ppat.1014474

Vancouver

Foulkes DM, Fernig DG, McLean K, Held M, Harris JA, Sun Y, et al. Topical formulation of repurposed FDA-approved compounds inhibits Pseudomonas aeruginosa ExoU and improves corneal infection outcomes. PLOS Pathogens. 2026;22(8):e1014474. doi:10.1371/journal.ppat.1014474

BibTeX
@article{Foulkes2026,
  author = {Foulkes, Daniel M and Fernig, David G and McLean, Keri and Held, Marie and Harris, John A and Sun, Yan and Fothergill, Joanne L and Price, Valerie and Byrne, Dominic P and Czanner, Gabriela and Tam, Connie and Kaye, Stephen B},
  title = {Topical formulation of repurposed FDA-approved compounds inhibits Pseudomonas aeruginosa ExoU and improves corneal infection outcomes},
  journal = {PLOS Pathogens},
  year = {2026},
  volume = {22},
  number = {8},
  pages = {e1014474},
  doi = {10.1371/journal.ppat.1014474}
}
Kostenlos starten →